The European Commission has approved Roche and ImmunoGen's Kadcyla, or trastuzumab emtansine, as a treatment for HER-2 positive metastatic breast cancer. The approval was based on data from a late-stage trial that showed Kadcyla improved overall survival, compared with standard therapy. Based on the approval, Roche will pay ImmunoGen a $5 million milestone fee.

Related Summaries